CTLA4 and non-small cell lung carcinoma: Two examples of such clinical trials are the ongoing phase Ib trial NIBIT-M4 (EUDRACT 2015-001329-17), combining guadecitabine and an anti-CTLA-4 monoclonal antibody (ipilimumab) in metastatic melanoma, and the randomized phase II trial NCT01928576 combining an “epigenetic priming” with azacytidine/oral azacytidine, given alone or in association with entinostat, with anti-PD-1 immunotherapy in patients with non-small cell lung cancer.